Brief: Elevation Oncology Inc Says Phase 1 SYSA1801 (Eo-3021) Clinical Initial Data Showed Promising Signs Of Efficacy

Elevation Oncology

03/06/2023 14:19

June 3 (Reuters) - Elevation Oncology Inc  ELEV.O :
    * ELEVATION ONCOLOGY HIGHLIGHTS FIRST-IN-HUMAN PHASE 1
SYSA1801
(EO-3021) CLINICAL DATA TO BE PRESENTED BY PARTNER CSPC
PHARMACEUTICAL GROUP LIMITED AT ASCO 2023
    * ELEVATION ONCOLOGY INC SAYS INITIAL DATA SHOWED PROMISING
SIGNS
OF EFFICACY
    * ELEVATION - DATA SHOWS A 47.1% ORR IN PATIENTS WITH
RESISTANT/REFRACTORY GASTRIC CANCER EXPRESSING CLAUDIN 18.2,
WITH A WELL-TOLERATED SAFETY PROFILE
    * ELEVATION ONCOLOGY INC SAYS ELEVATION ONCOLOGY ON TRACK TO
INITIATE PHASE 1 CLINICAL TRIAL IN US IN SECOND HALF OF 2023

Source text for Eikon:  ID:nPn1HbDla 
Further company coverage:  ELEV.O 

 ((Reuters.Briefs@thomsonreuters.com;))